We investigated the pharmacokinetics of
desferrioxamine and its chelated compounds
aluminoxamine and
ferrioxamine in normal volunteers and haemodialysis patients with and without
iron overload.
Desferrioxamine was administered in a single dose of 30 mg per kg
body-weight was a 30-min infusion to five healthy volunteers and to 20 haemodialysis patients (five patients without haemosiderosis and 15 patients with haemosiderosis). The interdialytic half-life of
ferrioxamine was 2.2 h in normal volunteers, 13.3 h in dialysis patients without haemosiderosis, and 24.6 h in patients with haemosiderosis. There was no interdialytic elimination of
aluminoxamine. In a second study, seven dialysis patients received 5, 10, and 20 mg per kg
body-weight desferrioxamine in a random order with a time interval of 2 weeks. The peak serum concentrations after these doses were 4.1 +/- 2.9, 6.4 +/- 2.9, and 10.7 +/- 7.1 mumol/l for
ferrioxamine and 2.8 +/- 1.5, 3.1 +/- 1.5, and 4.2 +/- 1.7 mumol/l for
aluminoxamine. Thus, a 4-fold increase in
desferrioxamine dosage resulted in a 2.7-fold increase in peak
ferrioxamine levels and in only a 1.5-fold increase in peak
aluminoxamine levels. We conclude that dialysis patients, especially those with haemosiderosis, are exposed to persistently elevated
ferrioxamine levels. Weekly doses of 5-10 mg/kg of
desferrioxamine would be sufficient for
aluminium chelation therapy.